lyogenix.com · research use only
Printed: 28/07/2026
For Research Use Only — Not for Human Consumption
This product is strictly intended for in-vitro research and laboratory use by qualified researchers. It is not approved for human or veterinary therapeutic use, self-administration, or any clinical application.
Retatrutide 60 mg
GLP-1/GIP/Glucagon Triple Agonist — High-Dose Vial
60 mg lyophilized powder + 3 mL sterile water
Overview
Retatrutide is a first-in-class triple agonist targeting three incretin and metabolic receptors simultaneously: GLP-1, GIP, and glucagon receptors. This high-dose 60 mg vial supports extended research protocols and multi-point dose-response studies from a single reconstituted vial, adding glucagon receptor activation to the dual GIP/GLP-1 approach pioneered by Tirzepatide.
Early clinical trial data have shown unprecedented weight reduction results, with the glucagon component adding direct hepatic fat oxidation and thermogenic energy expenditure beyond what dual agonists achieve.
Chemical Profile
| Property | Details |
|---|---|
| Molecular Weight | ~4605 Da |
| Purity | ≥98% (HPLC verified) |
| Form | Lyophilized Powder |
| Appearance | White to off-white powder |
| Solubility | Sterile water, saline |
| Storage | 2°C – 8°C, protect from light |
Mechanism of Action
Retatrutide simultaneously activates three metabolic receptors. GLP-1R activation provides appetite suppression, glucose-dependent insulin secretion, and delayed gastric emptying. GIPR activation enhances beta-cell function and may improve adipocyte metabolism.
The glucagon receptor (GCGR) component distinguishes Retatrutide from dual agonists: activation in hepatocytes stimulates glycogenolysis, gluconeogenesis, and critically, hepatic fatty acid oxidation — promoting direct energy expenditure through thermogenesis.
The triple agonism creates a synergistic metabolic effect addressing both sides of the energy balance equation simultaneously.
Research Applications
- Triple incretin receptor agonism pharmacology
- High-dose and extended dose-response research
- Glucagon receptor-mediated energy expenditure
- Hepatic lipid metabolism and NAFLD research
- Thermogenesis and energy expenditure
- Comparative incretin agonist studies
- Metabolic syndrome models
Product Specifications
- 1 × Vial (10R) containing Retatrutide lyophilized powder (60 mg)
- 1 × Ampoule Sterile Water for Injection (3 mL)
- Storage: 2°C – 8°C, protect from light
- Shelf life: 24 months (unopened, properly stored)
Ingredients
Retatrutide (60 mg), Mannitol, Sucrose
Certificate of Analysis
Full CoA with HPLC purity data and mass spectrometry confirmation is available for every batch.
Request CoARelated Products
Disclaimer
This product is intended for research and laboratory use only. Not for human consumption. LyoGenix Labs Pvt. Ltd. does not condone or promote the use of these compounds outside of legitimate research.
Authenticity Guarantee
Every LyoGenix product ships with a unique scratch code under a tamper-evident holographic label. Scratch the label to reveal your code and verify it here — confirming your product is genuine.
- Cryptographically unique code per box
- One-time verification — tracks first use
- Genuine LyoGenix Labs guarantee